Fundz
New|Fundz now works inside Claude2 min

See what’s changing first. Know which accounts matter next.

Fundz catches funding rounds before they’re announced, and acquisitions, new executives, hiring shifts and contract wins as they happen. It weighs them against your ideal customer profile and delivers a ranked shortlist every morning, with the evidence, the reason to reach out and the decision maker to contact. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.

Trusted by

OracleSnowflakeCloudflareLinkedInGoogleSalesforce
4.8/5 on G2· Since 2015

Merck enters $2.13 billion agreement with SciBrunch to license preclinical KRAS inhibitor SPR2015.

Sep 28, 2026

Contract Type

agreement

Pembroke PinesManufacturingBiotechnologyHealthcareHealth Care

Description

Merck has signed a substantial agreement worth up to $2.13 billion with SciBrunch Therapeutics to gain exclusive global rights to the preclinical oral KRAS inhibitor SPR2015. The deal involves an upfront payment of $400 million and potential milestone payments, marking a significant expansion for Merck's oncology pipeline.

Company Information

Company

Merck

Location

19700 STIRLING ROAD

Pembroke Pines, Florida, United States

About

For over 130 years, Merck, known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases in pursuit of our mission to save and improve lives. We demonstrate our commitment to patients and population health by increasing access to health care through far-reaching policies, programs and partnerships. Today, Merck continues to be at the forefront of research to prevent and treat diseases that threaten people and animals – including cancer, infectious diseases such as HIV and Ebola, and emerging animal diseases – as we aspire to be the premier research-intensive biopharmaceutical company in the world. For more information, visit www.merck.com and connect with us on Twitter, Facebook, Instagram, YouTube and LinkedIn.

Related People

Fadi
Senior decision-maker at this company
••••••••@••••••••

See Fadi's verified email →

Pranav
Senior decision-maker at this company
••••••••@••••••••

See Pranav's verified email →

Predictive Intelligence
Strategic

ML-powered predictions for Merck's next move

Learn about Strategic plan

Merck signed a new agreement. Fundz surfaces partnerships and contracts as they are announced.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.